Bepridil is potent against SARS-CoV-2 in vitro

^aThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843;
^bDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555;
^cDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843;
^dCenter of Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX 77555;
^eInstitute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX 77030;
^fDepartment of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, TX 77030;
^gDepartment of Molecular and Cellular Medicine, College of Medicine, Texas A&M University, College Station, TX 77843

Edited by Amy C. Rosenzweig, Northwestern University, Evanston, IL, and approved January 12, 2021 (received for review June 12, 2020)

Footnotes

↵¹E.C.V., K.S.Y., A.K.D., and K.C.K. contributed equally to this work.
↵²To whom correspondence may be addressed. Email: sktseng{at}utmb.edu or wliu{at}chem.tamu.edu.

Author contributions: S.X., C.-T.K.T., and W.R.L. designed research; E.C.V., K.S.Y., A.K.D., K.C.K., C.-C.C., K.R.K., J.C.H., and D.M.M. performed research; E.C.V., K.S.Y., A.K.D., K.C.K., C.-C.C., S.X., C.-T.K.T., and W.R.L. analyzed data; and W.R.L. wrote the paper.
The authors declare no competing interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2012201118/-/DCSupplemental.